Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009

AIDS

Volumn 27, Issue 5, 2013, Pages 803-813

  Abgrall, Sophie ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXY 2' FLUOROADENOSINE; 3' FLUOROTHYMIDINE; 6 CHLORO 4 (2 CYCLOPROPYLVINYL) 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; ABACAVIR PLUS LAMIVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; CAPRAVIRINE; DELAVIRDINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMIVIRINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOVIRIDE; MOZENAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TIPRANAVIR; UNINDEXED DRUG; VICRIVIROC; ZALCITABINE;

ADOLESCENT; ADULT; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG SAFETY; EUROPE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; NORTH AMERICA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT DURATION; VIRUS LOAD; VIRUS TRANSMISSION;

ADENINE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; COHORT STUDIES; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; DRUG COMBINATIONS; EUROPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV SEROPOSITIVITY; HIV-1; HUMANS; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; ORGANOPHOSPHONATES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 84876410870     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835cb997     Document Type: Review

References (45)

1. Sterne JA, Hernan MA, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Long-termeffectiveness of potent antiretroviral therapy in preventing AIDS and death: A prospective cohort study. Lancet 2005; 366:378-384.
2. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD, HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era, changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27-34.
3. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, et al. Antiretroviral treatment of Adult HIV infection: 2010 recommendations of the International AIDS Society-USA Panel. JAMA 2010; 304:321-333.
4. http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/ adultandadolescentgl.pdf Updated in 27/03/2012.
5. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
6. Hammer SM. Clinical practice: management of newly diagnosed HIV infection. N Engl J Med 2005; 353:1702-1710.
7. Hirsch MS, Conway B, d'Aquila RT, Johnson VA, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society: USA Panel. JAMA 1998; 279: 1984-1991.
8. World Health Organization (WHO) Guidelines. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. http://whqlibdoc.who.int/publications/2010/ 9789241599764-eng.pdf [Accessed 29 November 2010].
9. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of Adult HIV infection: 2008 recommendations of the International AIDS Society- USA Panel. JAMA 2008; 300:555-570.
10. Elzi L, Marzolini C, Furrer H, Ledergerber B, Cavassini M, Hirschel B, et al. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med 2010; 170:57-65.
11. Grabar S, Pradier C, Le Corfec E, Lancar R, Allavena C, Bentata M, et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS 2000; 14:141-149.
12. Binquet C, Chêne G, Jacqmin-Gadda H, Journot V, Savès M, Lacoste D, Dabis F, Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. Modeling changes in CD4-positive T-lymphocyte counts after the start of highly active antiretroviral therapy and the relation with risk of opportunistic infections: the Aquitaine Cohort, 1996-1997. Am J Epidemiol 2001; 153:386-393.
13. Gras L, Kesselring AM, Griffin JT, van Sighem AI, Fraser C, Ghani AC, et al. CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr 2007; 45:183-192.
14. D'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.C.O.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000; 14:499-507.
15. Swiss HIV Cohort Study, Schoeni-Affolter F, Ledergerber B, Rickenbach M, Rudin C, Günthard HF, Telenti A, et al. Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol 2010; 39:1179-1189.
16. Fätkenheuer G, Theisen A, Rockstroh J, Grabow T, Wicke C, Becker K, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997; 11:F113-F116.
17. Lundgren JD, Phillips AN, Vella S, Katlama C, Ledergerber B, Johnson AM, et al. Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. Euro SIDA Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:153-160.
18. Mocroft A, Barry S, Sabin CA, Lepri AC, Kinloch S, Drinkwater A, et al. The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997 Royal Free Centre for HIV Medicine. AIDS 1999; 13:1255-1261.
19. Hogg RS, Yip B, Kully C, Craib KJ, O'Shaughnessy MV, Schechter MT, Montaner JS. Improved survival among HIVinfected patients after initiation of triple-drug antiretroviral regimens. CMAJ 1999; 160:659-665.
20. Mocroft A, Gill MJ, Davidson W, Phillips AN. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS 1998; 12:2161-2167.
21. Jaén A, Casabona J, Esteve A, Miro JM, Tural C, Ferrer E, et al. Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project. Med Clin (Barc) 2005; 124:525-531.
22. Caro-Murillo AM, Castilla J, Pérez-Hoyos S, Miro JM, Podzamczer D, Rubio R, et al. Spanish cohort of naive HIV-infected patients (CoRIS): rationale, organization and initial results. Enferm Infecc Microbiol Clin 2007; 25:23-31.
23. Chen RY, Accortt NA, Westfall AO, Mugavero MJ, Raper JL, Cloud GA, et al. Distribution of healthcare expenditures for HIV-infected patients. Clin Infect Dis 2006; 42:1003-1010.
24. Kitahata MM, Dillingham PW, Chaiyakunapruk N, Buskin SE, Jones JL, Harrington RD, et al. Electronic human immunodeficiency virus (HIV) clinical reminder system improves adherence to practice guidelines among the University of Washington HIV Study Cohort. Clin Infect Dis 2003; 36:803-811.
25. Justice AC, Dombrowski E, Conigliaro J, Fultz SL, Gibson D, Madenwald T, et al. Veterans Aging Cohort Study (VACS): overview and description. Med Care 2006; 44 (8 Suppl 2): S13-S24.
26. Anderson KB, Guest JL, Rimland D. Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. Clin Infect Dis 2004; 39:1507-1513.
27. Shepherd BE, Jenkins CA, Rebeiro PF, Stinnette SE, Bebawy SS, McGowan CC, et al. Estimating the optimal CD4 count for HIV infected persons to start antiretroviral therapy. Epidemiology 2010; 21:698-705.
28. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multistate models. Statist Med 2007; 26:2389- 2430.
29. Klein JP, Andersen PK. Regression modeling of competing risks data based on pseudovalues of the cumulative incidence function. Biometrics 2005; 61:223-229.
30. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, et al. CD4+ count-guided interruption of antiretroviral treatment. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. N Engl J Med 2006; 355:2283-2296.
31. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment of Adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002; 288:222- 235.
32. Grabar S, Kousignian I, Sobel A, Le Bras P, Gasnault J, Enel P, et al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS 2004; 18:2029- 2038.
33. Keiser O, Orrell C, Egger M, Wood R, Brinkhof MW, Furrer H, et al. Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. Plos Med 2008; 5:1102-1111.
34. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients. A case-control study nested within the French Hospital Database on HIV ANRS Cohort CO4. Arch Intern Med 2010; 170:1228-1238.
35. Chen RY, Westfall AO, Mugavero MJ, Cloud GA, Raper JL, Chatham AG, et al. Duration of highly active antiretroviral therapy regimens. Clin Infect Dis 2003; 37:714-722.
36. Spire B, Carrieri P, Garzot MA, L'henaff M, Obadia Y, TRT-5 Group. Factors associated with efavirenz interruption in a large community-based sample of patients. AIDS Care 2004; 16:558- 564.
37. Mocroft A, Phillips AN, Soriano V, Rockstroh J, Blaxhult A, Katlama C, et al. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005; 21:743-752.
38. Yuan Y, L'italien G, Mukherjee J, Iloeje UH. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med 2006; 7:156-162.
39. Willig JH, Abroms S, Westfall AO, Routman J, Adusumilli S, Varshney M, et al. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008; 22:1951-1960.
40. When to Start Consortium, Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: A collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352- 1363.
41. Baylor MS, Johann-Liang R. Hepatotoxicity associated with mevirapine use. J Acquir Immune Defic Syndr 2004; 35:538- 539.
42. Murri R, Lepri AC, Phillips AN, Girardi E, Nasti G, Ferrara S, et al. Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex. Evidence from the I.Co.N.A. study. J Acquir Immune Defic Syndr 2003; 34:184-190.
43. Mehta U, Maartens G. Is it safe to switch between efavirenz and nevirapine in the event of toxicity? Lancet Infect Dis 2007; 7:733-738.
44. Lodwick RK, Smith CJ, Youle M, Lampe FC, Tyrer M, Bhagani S, et al. Stability of antiretroviral regimens in patients with viral suppression. AIDS 2008; 22:1030-1046.
45. Pujades-Rodriguez M, O'Brien D, Humblet P, Calmy A. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières. AIDS 2008; 22:1305-1312.